| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addendum
|
|
|
2014
|
19 |
4 |
p. 520-
1 p.
|
artikel
|
| 2 |
Big data in biomedicine
|
Costa, Fabricio F.
|
|
2014
|
19 |
4 |
p. 433-440
8 p.
|
artikel
|
| 3 |
Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface
|
Andrews, David M.
|
|
2014
|
19 |
4 |
p. 496-501
6 p.
|
artikel
|
| 4 |
Contents page 2
|
|
|
2014
|
19 |
4 |
p. iii-
1 p.
|
artikel
|
| 5 |
Contents page 1
|
|
|
2014
|
19 |
4 |
p. i-
1 p.
|
artikel
|
| 6 |
Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records
|
Wing, Kevin
|
|
2014
|
19 |
4 |
p. 361-366
6 p.
|
artikel
|
| 7 |
DREADDs: novel tools for drug discovery and development
|
Lee, Hyeong-Min
|
|
2014
|
19 |
4 |
p. 469-473
5 p.
|
artikel
|
| 8 |
Fragile X syndrome neurobiology translates into rational therapy
|
Braat, Sien
|
|
2014
|
19 |
4 |
p. 510-519
10 p.
|
artikel
|
| 9 |
Glutaminase regulation in cancer cells: a druggable chain of events
|
Katt, William P.
|
|
2014
|
19 |
4 |
p. 450-457
8 p.
|
artikel
|
| 10 |
How drug-like are ‘ugly’ drugs: do drug-likeness metrics predict ADME behaviour in humans?
|
Ritchie, Timothy J.
|
|
2014
|
19 |
4 |
p. 489-495
7 p.
|
artikel
|
| 11 |
In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations
|
Almeida, Hugo
|
|
2014
|
19 |
4 |
p. 400-412
13 p.
|
artikel
|
| 12 |
KV7 potassium channels: a new therapeutic target in smooth muscle disorders
|
Stott, Jennifer B.
|
|
2014
|
19 |
4 |
p. 413-424
12 p.
|
artikel
|
| 13 |
Learning from ‘big data’: compounds and targets
|
Hu, Ye
|
|
2014
|
19 |
4 |
p. 357-360
4 p.
|
artikel
|
| 14 |
Magnetic nanoparticles: a novel platform for cancer theranostics
|
Singh, Abhalaxmi
|
|
2014
|
19 |
4 |
p. 474-481
8 p.
|
artikel
|
| 15 |
May disordered protein cause serious drug side effect?
|
Tou, Weng Ieong
|
|
2014
|
19 |
4 |
p. 367-372
6 p.
|
artikel
|
| 16 |
Moving forward in clinical trials for ALS: motor neurons lead the way please
|
Genç, Barış
|
|
2014
|
19 |
4 |
p. 441-449
9 p.
|
artikel
|
| 17 |
mRNA display: from basic principles to macrocycle drug discovery
|
Josephson, Kristopher
|
|
2014
|
19 |
4 |
p. 388-399
12 p.
|
artikel
|
| 18 |
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
|
Barbieri, Federica
|
|
2014
|
19 |
4 |
p. 458-468
11 p.
|
artikel
|
| 19 |
NF-κβ signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities
|
Killeen, Matthew J.
|
|
2014
|
19 |
4 |
p. 373-378
6 p.
|
artikel
|
| 20 |
Phosphoproteomics in drug discovery
|
Morris, Melody K.
|
|
2014
|
19 |
4 |
p. 425-432
8 p.
|
artikel
|
| 21 |
Recent progress in development of new sonosensitizers for sonodynamic cancer therapy
|
Chen, Haijun
|
|
2014
|
19 |
4 |
p. 502-509
8 p.
|
artikel
|
| 22 |
The end of KRAS, and other, cancers? A new way forward
|
Mallucci, Livio
|
|
2014
|
19 |
4 |
p. 383-387
5 p.
|
artikel
|
| 23 |
Toll-like receptors as therapeutic targets for cancer
|
Holldack, Johanna
|
|
2014
|
19 |
4 |
p. 379-382
4 p.
|
artikel
|
| 24 |
Triterpenoids as reversal agents for anticancer drug resistance treatment
|
Yan, Xiao-Jian
|
|
2014
|
19 |
4 |
p. 482-488
7 p.
|
artikel
|
Tijdschrift beschrijving